ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• Enzon Pharmaceuticals, Inc. (ENZN) filed an 8-K (Item 7.01) on March 19, 2026 announcing an extension of its exchange offer for Series C Non-Convertible Redeemable Preferred Stock. The offer now expires at 5:00 p.m., Eastern time, on March 24, 2026, unless further extended. A press release dated March 19, 2026 was attached as Exhibit 99.1.
• The disclosure is presented in the context of Enzon’s proposed merger with Viskase Companies, Inc.; Enzon has filed a registration statement on Form S-4 with the SEC that includes the prospectus, consent solicitation statement and offer to exchange for the transaction.

Key Details

• New expiration: 5:00 p.m. Eastern on March 24, 2026 (offer may be further extended).
• Securities involved: Series C Non-Convertible Redeemable Preferred Stock to be exchanged for Enzon common stock ($0.01 par value).
• Related filing: Registration Statement on Form S-4 for the Enzon–Viskase transaction is available on SEC.gov and Enzon’s website (https://www.enzon.com).
• The 8-K includes forward-looking statement disclosures and lists material risks including closing conditions, timing uncertainties, Viskase’s delivery of required financial statements, and other transaction-related risks.

Why It Matters

• This extension gives holders more time to decide whether to exchange Series C preferred shares for common stock; any accepted exchanges will affect Enzon’s outstanding common shares and investor ownership proportions.
• The exchange offer and the S-4 are part of steps toward the proposed merger with Viskase—readers should review the Form S-4 and the risk factors in that filing for details about the combined company’s financials and transaction risks.
• Retail investors should monitor further updates (including any additional extensions or the final results of the exchange offer) because outcomes can influence share count, voting power, and potential transaction closing.